Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021
https://doi.org/10.58838/2075-1230-2023-101-3-62-68
Abstract
The objective: to evaluate the efficacy and safety of delamanid in a short-course treatment regimen for patients with MDR/pre-XDR pulmonary tuberculosis in Arkhangelsk Region from 2019 to 2021.
Subjects and Methods. 32 patients (4 with MDR TB and 28 with pre-XDR TB) started treatment with delamanid within the combination chemotherapy with new drugs, treatment lasted for 12 months. All patients with pre-XDR TB received delamanid, bedaquiline, linezolid, and clofazimine, then the chemotherapy regimen was compiled depending on the clinical situation.
Results. Effective treatment was registered in 21/32 patients (65,6%). 4/32 (12,5%) patients interrupted the treatment. Treatment failure was registered in 2/32 (6,25%). During the study, 5 (15,6%) patients died, in none of them tuberculosis was the cause of death. 106 adverse events (AEs) were reported, they included electrolyte imbalance (18,9%), hepatotoxic (16,0%), nephrotoxic (10,4%) and cardiotoxic (10,4%) reactions.
About the Authors
E. S. Khimova
Northern State Medical University; Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Elena S. Khimova, Assistant of Phthisiopulmonology Department, Phthisiologist
51, Troitsky Ave., Arkhangelsk, 163069
28, Novgorodsky Ave., Arkhangelsk, 163002
D. V. Perkhin
Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Dmitry V. Perkhin, Head Physician
28, Novgorodsky Ave., Arkhangelsk, 163002
O. M. Sveshnikova
Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Oksana M. Sveshnikova, Deputy Chief Physician for Medical Activities
28, Novgorodsky Ave., Arkhangelsk, 163002
S. V. Makhmaeva
Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Svetlana V. Makhmaeva, Head of MDR TB Treatment Department
28, Novgorodsky Ave., Arkhangelsk, 163002
V. N. Verkhovaya
Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Viktoria N. Verkhovaya, Phthisiologist of MDR TB Treatment Department
28, Novgorodsky Ave., Arkhangelsk, 163002
P. I. Eliseev
Northern State Medical University; Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Platon I. Eliseev, Candidate of Medical Sciences, Associate Professor of Phthisiopulmonology Department, Specialist of Clinical Laboratory Diagnostics
51, Troitsky Ave., Arkhangelsk, 163069
28, Novgorodsky Ave., Arkhangelsk, 163002
E. I. Nikishova
Northern State Medical University
Russian Federation
Russian Federation
Elena I. Nikishova, Doctor of Medical Sciences, Professor of Phthisiopulmonology Department
51, Troitsky Ave., Arkhangelsk, 163069
A. O. Maryandyshev
Northern State Medical University; Arkhangelsk Clinical TB Dispensary
Russian Federation
Russian Federation
Andrey O. Maryandyshev,Doctor of Medical Sciences, Professor, Correspondent Member of the Russian Academy of Sciences, Head of Phthisiopulmonology Department
51, Troitsky Ave., Arkhangelsk, 163069
28, Novgorodsky Ave., Arkhangelsk, 163002
References
1. Gayda A. I., Sveshnikova O. M., Verkhovaya V. N., Makhmaeva S. V., Nikishova E. I., Maryandyshev A. O. Treatment of tuberculosis patients with extensive drug resistance using new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 7, pp. 5–10. (In Russ.)
2. Lorsanov S. M., Khaydarkhanova Z. B., Khunkarsultanov S. B. The experience of using delamanid in the Chechen Republic. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 12, pp. 62–63. (In Russ.)
3. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. ISBN 978-92-4-003703-8
4. Maryandyshev A., Lorsanov S., Khaidarkhanova Z., Perkhin D., Sveshnikova O., Gaida A.,.Khimova E, Privolnev V. Delamanid in MDR/XDR pulmonary tuberculosis in Russia: first experience. European Congress of Clinical Microbiology and Infectious Diseases. Abstract book – 30th ECCMID 2020: Abstract 4394.
5. Maryandyshev A., Pontali E., Tiberi S., Akkerman O., Ganatra S., Sadutshang T., et al. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis // Emerg Infect Dis. – 2017. – Vol. 23, № 10. – P. 1718–1721.
6. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17–19 November 2020. Geneva: World Health Organization; 2021. ISBN 978-92-4-002219-5
7. Von Groote-Bidlingmaier F., Patientia R., Sanchez E., et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial // The Lancet Respiratory Medicine. – 2019. – Vol. 7, № 3. – Р. 249–259.
8. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. ISBN 978-92-4-000704-8
Review
For citations:
Khimova E.S., Perkhin D.V., Sveshnikova O.M., Makhmaeva S.V., Verkhovaya V.N., Eliseev P.I., Nikishova E.I., Maryandyshev A.O. Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021. Tuberculosis and Lung Diseases. 2023;101(3):62–68. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-3-62-68
Views:
511
Email this article 